The jury selection process in the trial of Martin Shkreli, the CEO of Mylan Pharmaceuticals, the company that raised the price of EpiPen, “an emergency allergy injection sold by Mylan,” lasted three days.1 “Shkreli was widely criticized for defending the 400 percent increase in the price of EpiPen. . . . More than two hundred potential jurors were excused from the trial.”2 Here are a few examples of the court’s voir dire:
January 31, 2019 Feature
Jury Selection: The Often-Overlooked Make-It-or-Break-It Phase of a Trial
By Dick Semerdjian and Janice Mulligan
Premium Content For:
- Tort Trial and Insurance Practice Section